Advances in the 5q-syndrome

Blood

Volumn 116, Issue 26, 2010, Pages 5803-5811

  Boultwood, Jacqueline ^a   Pellagatti, Andrea ^a   McKenzie, Andrew N J ^b   Wainscoat, James S ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FLT3 LIGAND; LENALIDOMIDE; MICRORNA; PROTEIN P53; RIBOSOME PROTEIN;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; BONE MARROW; CD34 SELECTION; CELL DEATH; CELL GROWTH; CHROMOSOME DELETION; COPY NUMBER VARIATION; CRITICAL DELETED REGION; CYTOGENETICS; DRUG MECHANISM; ERYTHROPOIESIS; FLUORESCENCE ACTIVATED CELL SORTING; FOOD AND DRUG ADMINISTRATION; GENE DELETION; GENE MAPPING; GENE MUTATION; GENOMIC INSTABILITY; GENOTYPE PHENOTYPE CORRELATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOPHENOTYPING; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MEGAKARYOCYTE; MEGALOCYTOSIS; MORPHOLOGY; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; THERAPY EFFECT; THROMBOCYTOSIS; TRANSLATION INITIATION; UNIPARENTAL DISOMY;

EID: 78650668810     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-04-273771     Document Type: Review

References (99)

1. Van den Berghe H, Cassiman JJ, David G, Fryns JP, Michaux JL, Sokal G. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature. 1974;251(5474):437-438.
2. Patnaik MM, Lasho TL, Finke CM, et al. WHO-defined 'myelodysplastic syndrome with isolated del (5q) in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPLand IDH mutations. Leukemia. 2010;24(7):1283-1289.
3. Nimer SD, Golde DW. The 5q-abnormality. Blood. 1987;70(6):1705-1712.
4. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood. 1994;84(10):3253-3260.
5. Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C. The 5q-syndrome. Hematology. 2004;9(4):271-277.
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292-2302.
7. Giagounidis AA, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res. 2006;12(1):5-10.
8. Giagounidis AA, Germing U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del (5q) including band q31. Leukemia. 2004;18(1):113-119.
9. van Leeuwen BH, Martinson ME, Webb GC, Young IG. Molecular organization of the cytokine gene cluster, involving the human IL-3, IL-4, IL-5, and GM-CSF genes, on human chromosome 5. Blood. 1989;73(5):1142-1148.
10. Roberts WM, Look AT, Roussel MF, Sherr CJ. Tandem linkage of human CSF-1 receptor (c-fms) and PDGF receptor genes. Cell. 1988;55(4):655-661.
11. Teerenhovi L, Lintula R, Ruutu T, Knuutila S. Correlation between bone marrow karyotype and the occurrence of erythroblast micronuclei and nuclear budding in patients with myelodysplastic syndromes. Eur J Haematol. 1987;39(3):237-240.
12. Jaju RJ, Jones M, Boultwood J, et al. Combined immunophenotyping and FISH identifies the involvement of B-cells in 5q-syndrome. Genes Chromosomes Cancer. 2000;29(3):276-280.
13. Nilsson L, Astrand-Grundstrom I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood. 2000;96(6):2012-2021.
14. Nilsson L, Eden P, Olsson E, et al. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood. 2007;110(8):3005-3014.
15. Garderet L, Kobari L, Mazurier C, et al. Unimpaired terminal erythroid differentiation and preserved enucleation capacity in myelodysplastic 5q (del) clones: a single cell study. Haematologica. 2010;95(3):398-405.
16. Ximeri M, Galanopoulos A, Klaus M, et al. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion. Haematologica. 2010;95(3):406-414.
17. Raaijmakers MH, Mukherjee S, Guo S, et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukaemia. Nature. 2010;464(7290):852-857.
18. Fidler C, Watkins F, Bowen DT, Littlewood TJ, Wainscoat JS, Boultwood J. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del (5q). Haematologica. 2004;89(7):865-866.
19. Crescenzi B, La Starza R, Romoli S, et al. Submicroscopic deletions in 5q-associated malignancies. Haematologica. 2004;89(3):281-285.
20. Ingram W, Lea NC, Cervera J, et al. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow. Leukemia. 2006;20(7):1319-1321.
21. Wang L, Fidler C, Nadig N, et al. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del (5q) using high-density single nucleotide polymorphism arrays. Haematologica. 2008;93(7):994-1000.
22. Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood. 2002;99(12):4638-4641.
23. Boultwood J, Fidler C, Lewis S, et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q-syndrome: delineation of the critical region on 5q and identification of a 5q-breakpoint. Genomics. 1994;19(3):425-432.
24. Jaju RJ, Boultwood J, Oliver FJ, et al. Molecular cytogenetic delineation of the critical deleted region in the 5q-syndrome. Genes Chromosomes Cancer. 1998;22(3):251-256.
25. Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34+ cells in patients with the 5q-syndrome. Br J Haematol. 2007;139(4):578-589.
26. Largaespada DA. Haploinsufficiency for tumor suppression: the hazards of being single and living along time. J Exp Med. 2001;193(4):F15-F18.
27. Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta. 2004;1654(2):105-122.
28. Ebert BL. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia. 2009;23(7):1252-1256.
29. Pellagatti A, Hellstrom-Lindberg E, Giagounidis A, et al. Haploinsufficiency of RPS14 in 5q-syndrome is associated with deregulation of ribosomal-and translation-related genes. Br J Haematol. 2008;142(1):57-64.
30. Montaville P, Dai Y, Cheung CY, et al. Nuclear translocation of the calcium-binding protein ALG-2 induced by the RNA-binding protein RBM22. Biochim Biophys Acta. 2006;1763(11):1335-1343.
31. Hellborg F, Qian W, Mendez-Vidal C, et al. Human wig-1, a p53 target gene that encodes a growth inhibitory zinc finger protein. Oncogene. 2001;20(39):5466-5474.
32. Park IK, Qian D, Kiel M, et al. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 2003;423(6937):302-305.
33. Steinbach D, Schramm A, Eggert A, et al. Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res. 2006;12(8):2434-2441.
34. Pellagatti A, Marafioti T, Paterson JC, et al. Induction of p53 and up-regulation of the p53 pathway in the human 5q-syndrome. Blood. 2010;115(13):2721-2723.
35. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a5q-syndrome gene by RNA interference screen. Nature. 2008;451(7176):335-339.
36. Barlow JL, Drynan LF, Hewett DR, et al. Ap53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q-syndrome. Nat Med. 2010;16(1):59-66.
37. Larkin JC, Thompson JR, Woolford JL Jr. Structure and expression of the Saccharomyces cerevisiae CRY1 gene: a highly conserved ribosomal protein gene. Mol Cell Biol. 1987;7(5):1764-1775.
38. Moritz M, Paulovich AG, Tsay YF, Woolford JL Jr. Depletion of yeast ribosomal proteins L16 or rp59 disrupts ribosome assembly. J Cell Biol. 1990;111(6 Pt 1):2261-2274.
39. Jakovljevic J, de Mayolo PA, Miles TD, et al. The carboxy-terminal extension of yeast ribosomal protein S14 is necessary for maturation of 43S preribosomes. Mol Cell. 2004;14(3):331-342.
40. Flygare J, Karlsson S. Diamond-Blackfan anemia: erythropoiesis lost in translation. Blood. 2007;109(8):3152-3154.
41. Lipton JM, Atsidaftos E, Zyskind I, Vlachos A. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer. 2006;46(5):558-564.
42. Ebert BL, Lee MM, Pretz JL, et al. An RNA interference model of RPS19 deficiency in Diamond-Blackfan anemia recapitulates defective hematopoiesis and rescue by dexamethasone: identification of dexamethasone-responsive genes by microarray. Blood. 2005;105(12):4620-4626.
43. Doherty L, Sheen MR, Vlachos A, et al. Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia. Am J Hum Genet. 2010;86(2):222-228.
44. Sridhar K, Ross DT, Tibshirani R, Butte AJ, Greenberg PL. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood. 2009;114(23):4847-4858.
45. Menne TF, Goyenechea B, Sanchez-Puig N, et al. The Shwachman-Bodian- Diamond syndrome protein mediates translational activation of ribosomes in yeast. Nat Genet. 2007;39(4):486-495.
46. Ganapathi KA, Shimamura A. Ribosomal dysfunction and inherited marrow failure. Br J Haematol. 2008;141(3):376-387.
47. Narla A, Ebert BL. Ribosomopathies: human disorders of ribosome dysfunction. Blood. 2010;115(16):3196-3205.
48. Cazzola M. Myelodysplastic syndrome with isolated 5q deletion (5q-syndrome). Aclonal stem cell disorder characterized by defective ribosome biogenesis. Haematologica. 2008;93(7):967-972.
49. Panic L, Montagne J, Cokaric M, Volarevic S. S6-haploinsufficiency activates the p53 tumor suppressor. Cell Cycle. 2007;6(1):20-24.
50. McGowan KA, Li JZ, Park CY, et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet. 2008;40(8):963-970.
51. Wade M, Wang YV, Wahl GM. The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol. 2010;20(5):299-309.
52. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem. 2000;275(12):8945-8951.
53. Zhang Y, Wolf GW, Bhat K, et al. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol. 2003;23(23):8902-8912.
54. Fumagalli S, Di Cara A, Neb-Gulati A, et al. Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nat Cell Biol. 2009;11(4):501-508.
55. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9(5):402-412.
56. Liu Y, Elf SE, Asai T, et al. The p53 tumor suppressor protein is a critical regulator of hematopoietic stem cell behavior. Cell Cycle. 2009;8(19):3120-3124.
57. Zhang Y, Lu H. Signaling to p53: ribosomal proteins find their way. Cancer Cell. 2009;16(5):369-377.
58. Danilova N, Sakamoto KM, Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood. 2008;112(13):5228-5237.
59. Jones NC, Lynn ML, Gaudenz K, et al. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. Nat Med. 2008;14(2):125-133.
60. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype. Nat Med. 2010;16(1):49-58.
61. Pietrancosta N, Moumen A, Dono R, et al. Iminotetrahydro-benzothiazole derivatives as p53 inhibitors: discovery of a highly potent in vivo inhibitor and its action mechanism. J Med Chem. 2006;49(12):3645-3652.
62. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5TOP mRNA translation through inhibition of p70s6k. EMBOJ. 1997;16(12):3693-3704.
63. Suzuki HI, Yamagata K, Sugimoto K, Iwamoto T, Kato S, Miyazono K. Modulation of micro RNA processing by p53. Nature. 2009;460(7254):529-533.
64. Sachdeva M, Zhu S, Wu F, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A. 2009;106(9):3207-3212.
65. Elia L, Quintavalle M, Zhang J, et al. The knockout of miR-143-and-145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease. Cell Death Differ. 2009;16(12):1590-1598.
66. Le Beau MM, Westbrook CA, Diaz MO, et al. Evidence for the involvement of GM-CSF and FMS in the deletion (5q) in myeloid disorders. Science. 1986;231(4741):984-987.
67. Willman CL, Sever CE, Pallavicini MG, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science. 1993;259(5097):968-971.
68. Liu TX, Becker MW, Jelinek J, et al. Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med. 2007;13(1):78-83.
69. Lehmann S, O'Kelly J, Raynaud S, Funk SE, Sage EH, Koeffler HP. Common deleted genes in the 5q-syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice. Leukemia. 2007;21(9):1931-1936.
70. Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q-syndrome patients. Proc Natl Acad Sci U S A. 2007;104(27):11406- 11411.
71. Joslin JM, Fernald AA, Tennant TR, et al. Haploinsufficiency of EGR1, a candidate gene in the del (5q), leads to the development of myeloid disorders. Blood. 2007;110(2):719-726.
72. Lane SW, Sykes SM, Al-Shahrour F, et al. The Apc (min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. Blood. 2010;115(17):3489-3497.
73. Sportoletti P, Grisendi S, Majid SM, et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood. 2008;111(7):3859-3862.
74. Lai F, Godley LA, Joslin J, et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with adel (5q). Genomics. 2001;71(2):235-245.
75. Zhao N, Stoffel A, Wang PW, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A. 1997;94(13):6948-6953.
76. Shannon KM, Le Beau MM, Largaespada DA, Killeen N. Modeling myeloid leukemia tumor suppressor gene inactivation in the mouse. Semin Cancer Biol. 2001;11(3):191-200.
77. Pellagatti A, Cazzola M, Giagounidis AA, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon- stimulated genes and correlation to FAB subtype and karyotype. Blood. 2006;108(1):337-345.
78. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol. 2001;19(5):1405-1413.
79. Jadersten M, Saft L, Pellagatti A, et al. Clonal heterogeneity in the 5q-syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica. 2009;94(12):1762-1766.
80. Sokol L, List AF. Immunomodulatory therapy for myelodysplastic syndromes. Int J Hematol. 2007;86(4):301-305.
81. Komrokji RS, List AF. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions. Hematol Oncol Clin North Am. 2010;24(2):377-388.
82. Fenaux P, Kelaidi C. Treatment of the 5q-syndrome. Hematology Am Soc Hematol Educ Program. 2006;192-198.
83. Cazzola M, Malcovati L. Myelodysplastic syndromes: coping with ineffective hematopoiesis. N Engl J Med. 2005;352(6):536-538.
84. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549-557.
85. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465.
86. European Medicines Agency. Withdrawal assessment report for Lenalidomide Celgene Europe. 2008. http://www.ema.europa.eu/docs/en-GB/document-library/ Application-withdrawal-assessment-report/2010/01/WC500065821.pdf. Accessed August 2010.
87. Gohring G, Giagounidis A, Busche G, et al. Patients with del (5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression. Ann Hematol. 2010;89(4):365-374.
88. Ebert BL, Galili N, Tamayo P, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med. 2008;5(2): e35.
89. Ortega J, List A. Immunomodulatory drugs in the treatment of myelodysplastic syndromes. Curr Opin Oncol. 2007;19(6):656-659.
90. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil? J Cell Biochem. 2004;92(4):679-690.
91. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injury. J Clin Invest. 2001;107(9):1049-1054.
92. Zhang LH, Schafer PH, Muller G, Stirling D, Bartlett B. Direct inhibitory effects of lenalidomide on the proliferation and VEGF production of non-Hodgkin lymphoma cells are associated with increased SPARC expression. Blood. 2008;112:905. Abstract 2612.
93. Wei S, Chen X, Rocha K, et al. A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide. Proc Natl Acad Sci U S A. 2009;106(31):12974-12979.
94. Wang J, Fernald AA, Anastasi J, Le Beau MM, Qian Z. Haploinsufficiency of Apc leads to ineffective hematopoiesis. Blood. 2010;115(17):3481-3488.
95. Testa U, Stellacci E, Pelosi E, et al. Impaired myelopoiesis in mice devoid of interferon regulatory factor 1. Leukemia. 2004;18(11):1864-1871.
96. Peng J, Kitchen SM, West RA, Sigler R, Eisenmann KM, Alberts AS. Myeloproliferative defects following targeting of the Drf1 gene encoding the mammalian diaphanous related formin mDia1. Cancer Res. 2007;67(16):7565-7571.
97. Dai XM, Ryan GR, Hapel AJ, et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood. 2002;99(1):111-120.
98. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature. 2005;437(7055):147-153.
99. Tehranchi R, Woll PS, Anderson K, et al. Persistent malignant stem cells in del (5q) myelodysplasia in remission. N Engl J Med. 2010;363(11):1025-1037.